To view this email as a web page, click here.
July 19, 2019
 
Treatment Intensification in Type 2 Diabetes: 3 Cases
When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?
(©molekuul.be/Shutterstock.com)

Read more
 
 
SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.

Read more
 
PLUS: RELATED TYPE 2 DIABETES CONTENT ON PATIENT CARE
 
Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications
First Oral GLP-1 Agonist Showcased while Approval Pending
Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.